Stephen Eck is a hematologist and oncologist with more than 25 years experience in academia and industry. He began his professional career at the University of Pennsylvania where he was Director of the Gene Therapy Program, and has since held a number of leaderships roles in oncology drug and biomarker development at prominent pharmaceutical companies. Prior to joining Immatics, Stephen Eck served as Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, and previously held senior roles at Pfizer and Eli Lilly. Whilst at Astellas Pharma, Dr.Eck worked closely with The University of Texas MD Anderson Cancer Center, a key collaborator of Immatics, on a number of clinical trials, joint collaborations and external advisory committees. He is former Chairman of the Board of Directors of the Personalized Medicine Coalition. Additionally, he is on the Board of Directors for Luminex Corporation and Circulogene and is a Fellow of the American Association for the Advancement of Science. Stephen Eck has a Ph.D. in Chemistry from Harvard University and an M.D. degree from the University of Mississippi School of Medicine.
The liquid biopsy market is expected to grow to as much as $30 billion by 2025. Many factors are…